

## **Strongbridge Biopharma plc to Present at the 27th Annual Oppenheimer Healthcare Conference and the 16th Annual Needham Healthcare Conference**

March 14, 2017 7:30 AM ET

DUBLIN, Ireland and TREVOSE, Pa., March 14, 2017 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq:SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that Matthew Pauls, president and chief executive officer, will present at the 27th Annual Oppenheimer Healthcare Conference and the 16th Annual Needham Healthcare Conference. The details of the conferences are as follows:

### **27th Annual Oppenheimer Healthcare Conference**

Tuesday, March 21 at 9:45 am ET

The Westin New York Grand Central, New York, NY

### **16th Annual Needham Healthcare Conference**

Wednesday, April 5 at 3:40 pm ET

The Westin New York Grand Central, New York, NY

The Company's presentations will be webcast live and archived on the "Events & Presentations" page in the Investor section of the Company's website at [www.strongbridgebio.com](http://www.strongbridgebio.com).

### **About Strongbridge Biopharma**

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. KEVEYIS has orphan drug exclusivity status in the U.S. through August 7, 2022. In addition to establishing this neuromuscular disease franchise, the Company has a clinical-stage pipeline of therapies for rare endocrine diseases. Strongbridge's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor currently being studied for the treatment of endogenous Cushing's syndrome, and COR-005, a next-generation somatostatin analog (SSA) being investigated for the treatment of acromegaly, with potential additional applications in Cushing's syndrome and neuroendocrine tumors. Both COR-003 and COR-005 have received orphan designation from the U.S. Food and Drug Administration and the European Medicines Agency. For more information, visit [www.strongbridgebio.com](http://www.strongbridgebio.com).

#### Contacts

Corporate and Media Relations  
Elixir Health Public Relations  
Lindsay Rocco  
+1 862-596-1304  
[lrocco@elixirhealthpr.com](mailto:lrocco@elixirhealthpr.com)

Investor Relations  
The Trout Group  
Marcy Nanus  
+1 646-378-2927  
[mnanus@troutgroup.com](mailto:mnanus@troutgroup.com)

USA  
900 Northbrook Drive  
Suite 200  
Trevose, PA 19053  
Tel. +1 610-254-9200  
Fax. +1 215-355-7389



Strongbridge Biopharma plc